Literature DB >> 21672496

Sudden deaths in psychiatric patients.

Peter Manu1, John M Kane, Christoph U Correll.   

Abstract

BACKGROUND: Studies using death certificates have indicated an excess of sudden cardiac deaths among users of antipsychotic drugs compared to the general population, but they may have underestimated the presence of other known causes of sudden and unexpected death.
OBJECTIVE: To assess the causes and risk factors for sudden death discovered by contemporaneous investigation of all deaths occurring over a 26-year period (1984-2009) in adults (119,500 patient-years) receiving care in one large psychiatric hospital in New York.
METHOD: Circumstances of death, psychiatric diagnoses, psychotropic drugs, and past medical history were extracted from the root cause analyses of sudden, unexpected deaths. After cases involving suicide, homicide, and drug overdoses were excluded, the remaining explained and unexplained cases of sudden death were compared regarding clinical variables and the utilization of antipsychotics.
RESULTS: One hundred cases of sudden death were identified. The death remained unexplained in 52 cases. The incidence of unexplained sudden death per 100,000 patient-years increased from 7 (95% CI, 3.7-19.4) in 1984-1998 to 125 (95% CI, 88.9-175.1) in 2005-2009. Explained and unexplained cases were similar regarding psychiatric diagnoses and use of all psychotropic classes, including first- and second-generation antipsychotics. Dyslipidemia (P = .012), diabetes (P = .054), and comorbid dyslipidemia and diabetes (P = .006) were more common in the unexplained group.
CONCLUSIONS: In a consecutive cohort of psychiatric patients, the unexplained sudden deaths were not associated with higher utilization of first- or second-generation antipsychotics. The role of diabetes and dyslipidemia as risk factors for sudden death in psychiatric patients requires careful longitudinal studies. © Copyright 2011 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21672496      PMCID: PMC3305794          DOI: 10.4088/JCP.10m06244gry

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  26 in total

1.  Task Force on Sudden Cardiac Death of the European Society of Cardiology.

Authors:  S G Priori; E Aliot; C Blomstrom-Lundqvist; L Bossaert; G Breithardt; P Brugada; A J Camm; R Cappato; S M Cobbe; C Di Mario; B J Maron; W J McKenna; A K Pedersen; U Ravens; P J Schwartz; M Trusz-Gluza; P Vardas; H J Wellens; D P Zipes
Journal:  Eur Heart J       Date:  2001-08       Impact factor: 29.983

Review 2.  United States Cholesterol Guidelines 2001: expanded scope of intensive low-density lipoprotein-lowering therapy.

Authors:  S M Grundy
Journal:  Am J Cardiol       Date:  2001-10-11       Impact factor: 2.778

3.  Antipsychotics and the risk of sudden cardiac death.

Authors:  W A Ray; S Meredith; P B Thapa; K G Meador; K Hall; K T Murray
Journal:  Arch Gen Psychiatry       Date:  2001-12

4.  Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data.

Authors:  Sean Hennessy; Warren B Bilker; Jill S Knauss; David J Margolis; Stephen E Kimmel; Robert F Reynolds; Dale B Glasser; Mary F Morrison; Brian L Strom
Journal:  BMJ       Date:  2002-11-09

5.  Quality of medical care and excess mortality in older patients with mental disorders.

Authors:  B G Druss; W D Bradford; R A Rosenheck; M J Radford; H M Krumholz
Journal:  Arch Gen Psychiatry       Date:  2001-06

6.  Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents.

Authors:  Dan W Haupt; Lisa C Rosenblatt; Edward Kim; Ross A Baker; Richard Whitehead; John W Newcomer
Journal:  Am J Psychiatry       Date:  2009-01-15       Impact factor: 18.112

Review 7.  Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.

Authors:  Peter M Haddad; Ian M Anderson
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 8.  Quetiapine versus other atypical antipsychotics for schizophrenia.

Authors:  Katja Komossa; Christine Rummel-Kluge; Franziska Schmid; Heike Hunger; Sandra Schwarz; Manit Srisurapanont; Werner Kissling; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

9.  Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs.

Authors:  Elaine H Morrato; Benjamin Druss; Daniel M Hartung; Robert J Valuck; Richard Allen; Elizabeth Campagna; John W Newcomer
Journal:  Arch Gen Psychiatry       Date:  2010-01

10.  Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes.

Authors:  Elaine H Morrato; John W Newcomer; Siddhesh Kamat; Onur Baser; James Harnett; Brian Cuffel
Journal:  Diabetes Care       Date:  2009-02-24       Impact factor: 19.112

View more
  18 in total

Review 1.  Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

Authors:  Marc De Hert; Johan Detraux; Ruud van Winkel; Weiping Yu; Christoph U Correll
Journal:  Nat Rev Endocrinol       Date:  2011-10-18       Impact factor: 43.330

2.  Medical Rapid Response in Psychiatry: Reasons for Activation and Immediate Outcome.

Authors:  Peter Manu; Kristy Loewenstein; Yankel J Girshman; Padam Bhatia; Maira Barnes; Joseph Whelan; Victoria A Solderitch; Liliana Rogozea; Marybeth McManus
Journal:  Psychiatr Q       Date:  2015-12

Review 3.  Chlorpromazine versus penfluridol for schizophrenia.

Authors:  Naemeh Nikvarz; Mostafa Vahedian; Navid Khalili
Journal:  Cochrane Database Syst Rev       Date:  2017-09-23

4.  Antipsychotic medications and sudden cardiac arrest: more than meets the eye?

Authors:  James Peacock; William Whang
Journal:  Heart Rhythm       Date:  2012-12-28       Impact factor: 6.343

5.  A common missense variant in the neuregulin 1 gene is associated with both schizophrenia and sudden cardiac death.

Authors:  Adriana Huertas-Vazquez; Carmen Teodorescu; Kyndaron Reinier; Audrey Uy-Evanado; Harpriya Chugh; Katherine Jerger; Jo Ayala; Karen Gunson; Jonathan Jui; Christopher Newton-Cheh; Christine M Albert; Sumeet S Chugh
Journal:  Heart Rhythm       Date:  2013-03-21       Impact factor: 6.343

Review 6.  Neuregulin as a heart failure therapy and mediator of reverse remodeling.

Authors:  Cristi L Galindo; Sergey Ryzhov; Douglas B Sawyer
Journal:  Curr Heart Fail Rep       Date:  2014-03

7.  Physical comorbidity and its relevance on mortality in schizophrenia: a naturalistic 12-year follow-up in general hospital admissions.

Authors:  Dieter Schoepf; Hardeep Uppal; Rahul Potluri; Reinhard Heun
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-08-13       Impact factor: 5.270

Review 8.  Managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approach.

Authors:  Matisyahu Shulman; Avraham Miller; Jason Misher; Aleksey Tentler
Journal:  J Multidiscip Healthc       Date:  2014-10-31

9.  Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database.

Authors:  Elisabetta Poluzzi; Emanuel Raschi; Ariola Koci; Ugo Moretti; Edoardo Spina; Elijah R Behr; Miriam Sturkenboom; Fabrizio De Ponti
Journal:  Drug Saf       Date:  2013-06       Impact factor: 5.606

Review 10.  Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions.

Authors:  Petter Andreas Ringen; John A Engh; Astrid B Birkenaes; Ingrid Dieset; Ole A Andreassen
Journal:  Front Psychiatry       Date:  2014-09-26       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.